02568nam 2200565 a 450 991078511550332120230828215644.01-282-80173-297866128017301-4416-6139-593-5043-529-2600-00-2715-X(CKB)2670000000047479(EBL)588365(OCoLC)700692367(SSID)ssj0000672353(PQKBManifestationID)11415321(PQKBTitleCode)TC0000672353(PQKBWorkID)10635189(PQKB)10381738(MiAaPQ)EBC588365(Au-PeEL)EBL588365(CaPaEBR)ebr10416258(EXLCZ)99267000000004747920101015d2006 uy 0engur|n|---|||||txtccrBiopharmaceuticals[electronic resource] /S.N. Jogdand1st ed.Mumbai [India] Himalaya Pub. House20061 online resource (283 p.)Description based upon print version of record.81-8318-620-3 Includes bibliographical references and index.COVER; CONTENTS; INTRODUCTION; MARKET FOR BIOPHARMACEUTICALS; BIOPHARMACEUTICAL INDUSTRY; BIOPHARMACEUTICAL SECTOR IN INDIA; DRUG DISCOVERY AND DRUG DESIGNING; PHARMACOKINETICS; CLINICAL TRIALS; REGULATORY; THERAPEUTIC PROTEINS; BLOOD PRODUCTS; MONOCLONAL ANTIBODIES; HORMONE THERAPY; VACCINE PRODUCTION-NEW DEVELOPMENTS; TRANSGENIC PRODUCTION OF BIOPHARMACEUTICALS; HUMAN GENE THERAPY; ANTISENSE TECHNOLOGY (DNA MEDICINES)Biopharmaceuticals are complex macromolecules created through the genetic manipulation of living organisms using gene cloning, recombinant DNA(gene splicing), or fusion technologies. Although small molecule drugs remain the standard treatment for disease, new strategies based on the engineering of proteins, genes and cell as therapeutic agents will revolutionize medicine in the coming decades. More than 20 percent of new medicines launched in 2003 were produced using biotechnology, nearly 80 percent of those under development either use use of biotechnology or are derived from it. The biopharmBiopharmaceuticsBiopharmaceutics.615/.7Jogdand S. N1478028MiAaPQMiAaPQMiAaPQBOOK9910785115503321Biopharmaceuticals3725726UNINA